Compare BlackRock TCP Capital Corp (TCPC) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BlackRock TCP Capital Corp vs 10X Genomics Inc — how do they compare? BlackRock TCP Capital Corp trades at $3.95 (market cap $327.64M), while 10X Genomics Inc trades at $57.03 (market cap $7.61B). The key difference: 10X Genomics Inc is far larger — about 23.2× BlackRock TCP Capital Corp's market cap, and BlackRock TCP Capital Corp pays a 19.46% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals.
| TCPC | TXG | |
|---|---|---|
Market Cap | $327.64M | $7.61B |
Sector | Financials | Health |
52-Week High | $7.26 | $58.57 |
52-Week Low | $3.13 | $11.34 |
Dividend Yield | 19.46% | — |
Enterprise Value | — | $7.14B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TCPC trades at $3.92, down 0.51% today, with a bullish technical signal from moving averages but overbought RSI readings. Recent Q2 2026 earnings beat expectations at $0.22 per share, and the company completed a $523 million portfolio sale to reduce leverage. However, fundamentals show negative revenue and net income trends, with a high P/S ratio of 70.7 but a discounted P/B of 0.59.
The outlook is mixed: strategic actions and dividend yield near 8.7% offer value, but declining revenue, negative ROE/ROA, and class-action lawsuits pose significant risks. Analyst consensus is cautious with 30.8% buy ratings, suggesting limited upside without fundamental improvement.
TXG (10x Genomics) trades at $56.95, down 2.77% on the day. The stock exhibits bullish technical signals with strong moving averages, though RSI levels suggest overbought conditions. Fundamentally, the company shows improving trends with Q2 2026 earnings beating estimates and a narrowing net loss margin from -41.23% in 2023 to -12.18% in 2026. Recent news highlights collaborations with Cleveland Clinic and acquisition of Proteintech Genomics, expanding multiomics capabilities.
Outlook: Growth potential exists through market expansion and innovation, but risks include persistent unprofitability and high valuation multiples. Analyst sentiment is mixed with a $46 consensus target below current price, indicating caution despite recent operational improvements.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BlackRock TCP Capital Corp
BlackRock TCP Capital Corp is a finance company specializing in middle-market lending. It aims for high returns through income and capital appreciation while prioritizing principal protection. The company invests in debt securities and earns revenue from interest payments, fees, and some equity appreciation.
Read more on TCPC →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
